News
Latest
Start-up Global Morpho Pharma announces Framatome has acquired an interest in the company to accelerate industrialization of medical radioisotope manufacturing solutions
Global Morpho Pharma has announced the acquisition by Framatome of a minority stake in the Nantes-based start-up. This capital increase will enable Global Morpho Pharma to accelerate the industrialization of its Lutetium-177 production technologies and to strengthen its research and development efforts.
29
07
02
10
Global Morpho Pharma SAS pursues its development with a new CEO
Nantes, October 2nd, 2019 The board of Global Morpho Pharma SAS has the pleasure to announce that François Zimmermann will take over the position of Chief Executive Officer of the company. François will be located in Nantes together with his growing expert team. The company will move to a new office shortly. Pierre-Marie Lemer, chairman […]
09
09
EANM 2019 – Booth 101: Global Morpho Pharma is waiting for you in Barcelona
Global Morpho Pharma, a strategic supplier of therapeutic radionuclides, invites you to visit its booth at the annual EANM gathering in Barcelona, Oct. 12-16. In presence of the group’s partners, SCK-CEN & Spectron RX, and its team of experts, the company will reveal its strategy to develop a global distribution network for medical radionuclides for […]
11
06
SNMMI 2019 – Booth 565: Global Morpho Pharma and Spectron RX team up in Anaheim
The Society of Nuclear Medicine and Molecular Imaging (SNMMI), a leading global force in the nuclear medicine community, will be hosting its 2019 edition of its annual congress in Anaheim, California from 22nd-25th June. A perfect opportunity for Global Morpho Pharma and its trusted Spectron RX to join forces under the same aegis. In fact, […]
09
10
SCK•CEN joins Global Morpho Pharma’s network and announces collaboration with IRE ELiT
Mol (Belgium), Nantes (France) and Fleurus (Belgium), 8 October 2018 The Belgian Nuclear Research Center (SCK•CEN) and Global Morpho Pharma today announced that they have signed a memorandum of understanding relative to the production and distribution of Good Manufacturing Practice grade therapeutics medical radionuclides. Under the terms of the agreement, SCK•CEN will join Global Morpho […]
01
10
Global Morpho Pharma introduced to the world at EANM 18
The annual EANM gathering (European Association of Nuclear Medicine) is widely acknowledged as the world’s most important nuclear medicine conference. This was the global stage chosen by Global Morpho Pharma for its first introduction to the world’s nuclear medicine community, in the presence of the group’s partners and team of experts. GMP unveiled its strategy to […]
27
06
Global Morpho Pharma and Spectron partner for GMP therapeutic radionuclide supply in the US
This year’s annual congress of the SNMMI (Society of Nuclear Medicine and Molecular Imaging), held in June in Philadelphia, was Global Morpho Pharma’s first appearance at an international event. To mark the occasion, the company finalised a new partnership deal with Spectron LLC. Spectron will thus become our primary partner in a new international structure […]
15
03
An outstanding founding team
Six experts of the nuclear medicine field came together with a common vision about the future of radiotherapeutics and radiotheranostics. With its cumulated century experience in the area this group identified the needs for the pharmaceutical industry and anticipated the very fast growth of this modality. Ahead of developing a new drug it is even […]